FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
Century Tower completes handovers two months ahead of schedule in Business Bay as wider delay…
Keturah founder pinpoints critical shifts that will transform the property landscape in 2026 Dubai, UAE,…
South Asia’s definitive thought leadership dialogue, The Times Group’s ET NOW Global Business Summit 2026…
M&D has appointed industry veteran Tom Rizzi as Chief Executive Officer effective January 1, 2026
A striking new architectural landmark has entered the luxury market at 1140 Summit Drive in…
Three Group Solutions has completed the deployment of a private 5G network across key Hutchison…